Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals
Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.
You may also be interested in...
Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.
The number of microbiome-based companies is growing with scientific breakthroughs in this area. Pierre Belichard, CEO of the French gut microbiome focused company Enterome, talked to Scrip at the Biotrinity 2017 meeting in London about its partnerships, pipeline progress and his plans for the future.
A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.